Projects In Knowledge - Continuing Medical Education (CME)

Latest Programs

A New Chemotherapy + Targeted Agent Regimen as Initial Treatment for Metastatic Colorectal Cancer

Dr. Meyerhardt
Chair

Oncology Article Review - The combination of the angiogenesis inhibitor, bevacizumab, and either FOLFOX or FOLFIRI is a standard first-line therapy for metastatic colorectal cancer (mCRC). Preliminary trials have suggested that the addition of the EGFR inhibitor, cetuximab, may also increase the benefit of treatment with FOLFIRI in patients with metastatic disease. Dr. Meyerhardt discusses results of the recent phase III CRYSTAL trial comparing FOLFIRI vs FOLFIRI+cetuximab as first-line therapy for mCRC and comments on the need to balance efficacy and cetuximab-related toxicities of this combination regimen in determining treatment of newly diagnosed patients. This article review is part of the Certificate Program in Advanced/Metastatic Colorectal Cancer. more »1

Management of Stage III, N2 NSCLC: A Virtual Thoracic Oncology Tumor Board

Dr. Herbst and Dr. Langer
Co-Chair

Oncology Webcast - Roy S. Herbst, MD, PhD, leads a renowned multidisciplinary faculty of experts in medical oncology, thoracic surgery, pulmonology, and radiation oncology in a virtual tumor board that reviews the case of a 55-year-old man with stage III, N2 NSCLC to illustrate the multitude of options available for staging and treatment. more »2

Case Study: Use of FRAX^® and Strategies for Management of Increased Fracture Risk in Postmenopausal Women with Osteopenia

Dr. Siris
Faculty

Osteoporosis Tx Reporter Newsletter - Dr. Ethel S. Siris determines treatment candidacy for a 65-year-old woman with osteopenia, using the new FRAX tool and the National Osteoporosis Foundation Clinician’s Guide to Prevention and Treatment of Osteoporosis to assess fracture risk. She also discusses current recommendations regarding calcium and vitamin D supplements, available agents for reducing fracture risk, and optimal follow-up for patients on therapy. more »3

Expert Insight Into: Relationship Between K-ras Mutation Status and Benefit of Anti-EGFR Antibodies in Advanced Colorectal Cancer

Dr. Saltz
Chair

Oncology Article Review - The results from this clinical study indicate that K-ras mutation status may be used as a biomarker to identify which patients with advanced colorectal cancer will reap the greatest benefit from cetuximab treatment. This article review is part of the Certificate Program in Advanced/Metastatic Colorectal Cancer. more »4

Expert Insight Into: Assessing the Clinical Utility of Serum CTX in Postmenopausal Osteoporosis and Its Use in Predicting Risk of Osteonecrosis of the Jaw

Dr. Lewiecki
Faculty

Osteoporosis Article Review - The bone turnover marker, sCTX, is a sensitive indicator of bone resorption in postmenopausal women receiving bisphosphonate therapy for osteoporosis and has proven useful in measuring response to treatment. Dr. E. Michael Lewiecki explores the use of this marker as a possible predictor of bisphosphonate-associated osteonecrosis of the jaw and comments on the incorporation of sCTX into current clinical practice. This article review is part of the Osteoporosis Compendium. more »5

Expert Insight Into: Is There a Meaningful Serum HBV DNA Cutoff Level for Therapeutic Decisions in HBeAg-Negative Chronic HBV Infection?

Dr. Tsai
Faculty

Gastroenterology Article Review - The availability of sensitive HBV DNA tests has raised the question of what DNA cut-off level should be used to differentiate between inactive chronic HBV carriers, who require regular follow-up only, and patients with HBeAg-negative chronic hepatitis B, who need treatment. A recent study demonstrates that there may be no single HBV DNA criterion that can be used in making this distinction. Dr. Tsai discusses these results and the study investigators' recommendations for identifying patients who need therapeutic intervention. more »6

Highlights from the AAN Annual Meeting

Dr. Miller and Dr. Markowitz
Chair and Faculty

Neurology Podcast Series - This podcast features highlights of MS presentations given at the 2009 AAN annual meeting. Guest faculty Clyde E. Markowitz, MD, reports on advances in MS pathophysiology/immunology, updates about neuromyelitis optica, the use of ocular coherence tomography to predict and assess vision outcomes, and advances in the use of MRI to assess MS patients. Aaron E. Miller, MD, provides updates on currently marketed MS therapies and discusses the latest efficacy and safety data on emerging MS therapies.

This course represents the second of two podcasts that are part of The Advanced Certificate Program: Multiple Sclerosis Management. Access the first podcast, Highlights of the First MS World Congress, by clicking here. more »7

Case Study: Chinese-Born HBeAg-Positive Pregnant Patient

Dr. Di Bisceglie and Dr. Han
Co-Chair and Faculty

Gastroenterology Tx Reporter Newsletter - Dr. Steven-Huy B. Han follows the case of a Chinese-born woman in her third trimester of pregnancy who is positive for HBsAg and HBeAg. His discussion demonstrates the management of chronic hepatitis B infection with consideration of both mother and baby. more »8

Expert Insight Into: Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients with Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2

Dr. Langer
Co-Chair

Oncology Article Review - Dr. Corey Langer discusses results from a phase II trial in this patient population comparing the epidermal growth factor receptor inhibitor erlotinib with combination chemotherapy of paclitaxel plus carboplatin, and comments on the study’s implications for patient management. This article review is part of the Advanced Certificate Program: Lung Cancer Management II. more »9

Expert Insight Into: Consolidation Therapy (Docetaxel) Stage III NSCLC

Dr. Langer
Co-Chair

Oncology Article Review - This course reviews a phase III randomized trial that explored the use of docetaxel consolidation following chemoradiation, and its effect on overall survival, in patients with stage III NSCLC. Dr. Corey Langer comments on the findings and potential new treatment strategies for these patients. This article review is part of the Advanced Certificate Program: Lung Cancer Management II. more »10

Browse Home » Gastroenterology » Infectious Diseases » Neurology » Oncology » Osteoporosis » Psychiatry » Women's Health » Latest News powered by:	Latest Programs A New Chemotherapy + Targeted Agent Regimen as Initial Treatment for Metastatic Colorectal Cancer Dr. Meyerhardt Chair Oncology Article Review - The combination of the angiogenesis inhibitor, bevacizumab, and either FOLFOX or FOLFIRI is a standard first-line therapy for metastatic colorectal cancer (mCRC). Preliminary trials have suggested that the addition of the EGFR inhibitor, cetuximab, may also increase the benefit of treatment with FOLFIRI in patients with metastatic disease. Dr. Meyerhardt discusses results of the recent phase III CRYSTAL trial comparing FOLFIRI vs FOLFIRI+cetuximab as first-line therapy for mCRC and comments on the need to balance efficacy and cetuximab-related toxicities of this combination regimen in determining treatment of newly diagnosed patients. This article review is part of the Certificate Program in Advanced/Metastatic Colorectal Cancer. more »1 Management of Stage III, N2 NSCLC: A Virtual Thoracic Oncology Tumor Board Dr. Herbst and Dr. Langer Co-Chair Oncology Webcast - Roy S. Herbst, MD, PhD, leads a renowned multidisciplinary faculty of experts in medical oncology, thoracic surgery, pulmonology, and radiation oncology in a virtual tumor board that reviews the case of a 55-year-old man with stage III, N2 NSCLC to illustrate the multitude of options available for staging and treatment. more »2 Case Study: Use of FRAX^® and Strategies for Management of Increased Fracture Risk in Postmenopausal Women with Osteopenia Dr. Siris Faculty Osteoporosis Tx Reporter Newsletter - Dr. Ethel S. Siris determines treatment candidacy for a 65-year-old woman with osteopenia, using the new FRAX tool and the National Osteoporosis Foundation Clinician’s Guide to Prevention and Treatment of Osteoporosis to assess fracture risk. She also discusses current recommendations regarding calcium and vitamin D supplements, available agents for reducing fracture risk, and optimal follow-up for patients on therapy. more »3 Expert Insight Into: Relationship Between K-ras Mutation Status and Benefit of Anti-EGFR Antibodies in Advanced Colorectal Cancer Dr. Saltz Chair Oncology Article Review - The results from this clinical study indicate that K-ras mutation status may be used as a biomarker to identify which patients with advanced colorectal cancer will reap the greatest benefit from cetuximab treatment. This article review is part of the Certificate Program in Advanced/Metastatic Colorectal Cancer. more »4 Expert Insight Into: Assessing the Clinical Utility of Serum CTX in Postmenopausal Osteoporosis and Its Use in Predicting Risk of Osteonecrosis of the Jaw Dr. Lewiecki Faculty Osteoporosis Article Review - The bone turnover marker, sCTX, is a sensitive indicator of bone resorption in postmenopausal women receiving bisphosphonate therapy for osteoporosis and has proven useful in measuring response to treatment. Dr. E. Michael Lewiecki explores the use of this marker as a possible predictor of bisphosphonate-associated osteonecrosis of the jaw and comments on the incorporation of sCTX into current clinical practice. This article review is part of the Osteoporosis Compendium. more »5 Expert Insight Into: Is There a Meaningful Serum HBV DNA Cutoff Level for Therapeutic Decisions in HBeAg-Negative Chronic HBV Infection? Dr. Tsai Faculty Gastroenterology Article Review - The availability of sensitive HBV DNA tests has raised the question of what DNA cut-off level should be used to differentiate between inactive chronic HBV carriers, who require regular follow-up only, and patients with HBeAg-negative chronic hepatitis B, who need treatment. A recent study demonstrates that there may be no single HBV DNA criterion that can be used in making this distinction. Dr. Tsai discusses these results and the study investigators' recommendations for identifying patients who need therapeutic intervention. more »6 Highlights from the AAN Annual Meeting Dr. Miller and Dr. Markowitz Chair and Faculty Neurology Podcast Series - This podcast features highlights of MS presentations given at the 2009 AAN annual meeting. Guest faculty Clyde E. Markowitz, MD, reports on advances in MS pathophysiology/immunology, updates about neuromyelitis optica, the use of ocular coherence tomography to predict and assess vision outcomes, and advances in the use of MRI to assess MS patients. Aaron E. Miller, MD, provides updates on currently marketed MS therapies and discusses the latest efficacy and safety data on emerging MS therapies. This course represents the second of two podcasts that are part of The Advanced Certificate Program: Multiple Sclerosis Management. Access the first podcast, Highlights of the First MS World Congress, by clicking here. more »7 Case Study: Chinese-Born HBeAg-Positive Pregnant Patient Dr. Di Bisceglie and Dr. Han Co-Chair and Faculty Gastroenterology Tx Reporter Newsletter - Dr. Steven-Huy B. Han follows the case of a Chinese-born woman in her third trimester of pregnancy who is positive for HBsAg and HBeAg. His discussion demonstrates the management of chronic hepatitis B infection with consideration of both mother and baby. more »8 Expert Insight Into: Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients with Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2 Dr. Langer Co-Chair Oncology Article Review - Dr. Corey Langer discusses results from a phase II trial in this patient population comparing the epidermal growth factor receptor inhibitor erlotinib with combination chemotherapy of paclitaxel plus carboplatin, and comments on the study’s implications for patient management. This article review is part of the Advanced Certificate Program: Lung Cancer Management II. more »9 Expert Insight Into: Consolidation Therapy (Docetaxel) Stage III NSCLC Dr. Langer Co-Chair Oncology Article Review - This course reviews a phase III randomized trial that explored the use of docetaxel consolidation following chemoradiation, and its effect on overall survival, in patients with stage III NSCLC. Dr. Corey Langer comments on the findings and potential new treatment strategies for these patients. This article review is part of the Advanced Certificate Program: Lung Cancer Management II. more »10	Featured Programs Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice Held in Conjunction with the IASLC 13th WCLC 2009 Free CME/CE Satellite Symposium Saturday, August 1, 2009 San Francisco, CA Management of Stage III, N2 NSCLC: Virtual Thoracic Oncology Tumor Board Available Now Breast Cancer Management II Coming Soon The Advanced Certificate Program: Multiple Sclerosis Management Available Now The Certificate Program in Advanced/Metastatic Colorectal Cancer *Available Now* Profiles in CML: Case-Based Approaches to Managing Resistance and Improving Outcomes *Webcast Available Now* Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities *New 2009 Program Available Now* The Advanced Certificate Program: Lung Cancer Management II *Available Now!* Mini- Symposia Unraveling the Complexities of Menopause Management Webcast Available Now Living Medical Textbook Oncology Women's Cancers Edition Webcast Available Now Targeting the Microtubule in Breast Cancer New Course of The Advanced Certificate Program: Breast Cancer Management Caring for Oncology Patients: Tips and Tools for Managing Targeted Therapy An Ongoing Online CME/CE Curriculum Available Now	Osteoporosis: A Focus on Fracture Prevention A Free CME/CE ISS Held in Conjunction with the ASBMR's 31st Annual Meeting September 11, 2009 Denver, Colorado Register Now Special Announcement Projects In Knowledge poster presented at DDW 2009 Survey Findings: HBV Management Among U.S. Clinicians *Read more...* The Advanced Certificate Program: Multiple Sclerosis Management II Coming Soon Living Medical Textbook Osteoporosis Fracture Prevention and Therapeutic Management Edition Osteoporosis Compendium New 2009 Program Available Now Brainstorming with the Experts Practical Approaches to the Complex World of HCV Living Medical Textbook Oncology Tumor Immunology and Immunotherapy: Metastatic Melanoma Edition A Sea Change in MS Treatment— The Potential of Small Molecules On-Demand Interactive Webcast Available Now The Advanced Certificate Program: Breast Cancer Management Certificate Program The Advanced Certificate Program: Management of Mood Disorders Register Today The Advanced Certificate Program: Lung Cancer Management Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities Certificate Program